Monoclonal Anti-CD123 Antibody, Mouse IgG1 (6H9E8)

Cat. No. / Size
Price
Availability
Qty
CD3-MY2036-25ug
$55.00
CD3-MY2036-200ug
$320.00
CD3-MY2036
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-CD123 Antibody, Mouse IgG1 (6H9E8) is recombinantly expressed in HEK293. It consists of human variable regions genetically fused to mouse IgG1 constant domains.

Antibody Type

Recombinant Monoclonal

Clone

6H9E8

Isotype

Mouse IgG1, Kappa

Host Species

Human

Reactivity

Human

Immunogen

Recombinant Human CD123 Protein is expressed from human 293T cells

Specificity

Specifically recognizes Human CD123 Protein.

Application

Flow Cytometry (Evaluation of the expression of CD123 on Human cells).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.01% PF68, with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

Background

Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.